Niagen Bioscience (NAGE) AI Stock Analysis

• Market Cap: $514.75M
• Dividend Yield: N/A
• Average Volume (3M): 910.09K
• Price to Earnings (P/E): 26.7
• Beta (1Y): 0.85
• Revenue Growth: 36.04%
• EPS Growth: 1240.00%
• Country: US
• Employees: 104
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.05
• Shares Outstanding: 79,806,140
• 10 Day Avg. Volume: 647,243
• 30 Day Avg. Volume: 910,092
• PEG Ratio: -0.22
• Price to Book (P/B): 9.84
• Price to Sales (P/S): 4.55
• P/FCF Ratio: 37.97
• Enterprise Value/Market Cap: 1.45
• Enterprise Value/Revenue: 5.99
• Enterprise Value/Gross Profit: 9.37
• Enterprise Value/Ebitda: 35.33
• 1Y Price Target: $16.33
• Price Target Upside: 150.84% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.18
• Revenue Forecast (FY): $127.29M

• Rating: 70 Outperform
• Price Target: $7.00 ▲(7.53% Upside)

Niagen Bioscience's overall stock score is driven by strong financial performance and positive corporate events, indicating robust growth potential. However, bearish technical indicators and a moderate valuation temper the outlook. The earnings call further supports a positive future trajectory, despite some regulatory challenges.

Positive Factors

Revenue Growth

The consistent revenue growth underscores the company's expanding market reach and product adoption, positioning it well for sustained long-term growth.

Cash Generation

Strong cash generation enhances financial flexibility and supports strategic investments, ensuring long-term operational resilience.

Strategic Partnerships

Strategic partnerships expand distribution channels and enhance market penetration, fostering long-term growth and competitive advantage.

Negative Factors

Regulatory Challenges

Regulatory hurdles could impact product offerings and market strategy, posing risks to growth and operational stability.

High Pricing Strategy

Premium pricing may restrict customer base and hinder market expansion, affecting long-term revenue growth potential.

Competitive Market

Intense competition and IP challenges can strain resources and impact market share, requiring strategic focus on differentiation and innovation.

Niagen Bioscience Business Overview & Revenue Model

Company Description

Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.

How the Company Makes Money

Niagen Bioscience generates revenue through the sale of its proprietary nicotinamide riboside-based dietary supplements, which are marketed under various brand names. The company's revenue model is predominantly driven by direct-to-consumer sales via its online platform, as well as partnerships with retailers and distributors that expand its market reach. Additionally, NAGE may engage in licensing agreements with other companies for the use of its patented NR technology, providing another stream of revenue. Key partnerships with research institutions also contribute to the company's credibility and market presence, potentially leading to collaborative product development and increased sales opportunities.

Niagen Bioscience Financial Statement Overview

Summary

Niagen Bioscience demonstrates strong financial health with significant improvements in profitability, revenue growth, and cash flow generation. The company's low leverage and high return on equity further enhance its financial stability, positioning it well for future growth.

Income Statement

Niagen Bioscience has shown a strong improvement in its income statement metrics over the TTM period. The company achieved a gross profit margin of 63.62% and a net profit margin of 15.24%, indicating efficient cost management and profitability. Revenue growth rate is robust at 7.23%, reflecting positive sales momentum. EBIT and EBITDA margins have also improved significantly, showcasing operational efficiency.

Balance Sheet

The balance sheet of Niagen Bioscience is stable with a low debt-to-equity ratio of 0.05, indicating low financial leverage and reduced risk. Return on equity is strong at 35.46%, suggesting effective use of equity capital to generate profits. The equity ratio stands at 72.02%, highlighting a solid equity base relative to total assets.

Cash Flow

Cash flow metrics are positive, with a free cash flow growth rate of 102.2% in the TTM period, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.95, reflecting efficient conversion of income into cash. The free cash flow to net income ratio is nearly 1, suggesting that the company effectively translates its profits into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	124.71M	99.60M	83.57M	72.05M	67.45M	59.26M
Gross Profit	79.68M	61.59M	50.78M	42.80M	41.49M	35.27M
EBITDA	21.14M	9.21M	-3.89M	-16.74M	-25.45M	-18.34M
Net Income	20.43M	8.55M	-4.94M	-16.54M	-27.13M	-19.93M
Balance Sheet
Total Assets	98.14M	68.28M	54.96M	54.06M	57.84M	38.36M
Cash, Cash Equivalents and Short-Term Investments	64.14M	44.51M	27.17M	20.29M	28.02M	16.50M
Total Debt	3.06M	2.65M	3.28M	4.26M	4.70M	1.64M
Total Liabilities	27.46M	22.18M	26.51M	25.39M	26.11M	21.93M
Stockholders Equity	70.68M	46.09M	28.46M	28.67M	31.73M	16.42M
Cash Flow
Free Cash Flow	21.15M	11.95M	6.97M	-15.43M	-24.57M	-10.74M
Operating Cash Flow	21.41M	12.11M	7.12M	-15.10M	-24.16M	-10.60M
Investing Cash Flow	-260.00K	-143.00K	-143.00K	-334.00K	-409.00K	-165.00K
Financing Cash Flow	10.74M	5.37M	-90.00K	7.65M	36.09M	8.65M

Niagen Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAGE, the sentiment is Negative. The current price of 6.51 is below the 20-day moving average (MA) of 6.79, below the 50-day MA of 7.14, and below the 200-day MA of 8.93, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 39.78 is Neutral, neither overbought nor oversold. The STOCH value of 16.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAGE.

Niagen Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAGE	70 Outperform	$514.75M	26.66	38.90%	―	36.04%	1240.00%
SEPN	61 Neutral	$1.20B	―	-22.38%	―	2147.20%	-269.99%
FTRE	56 Neutral	$1.32B	―	-98.13%	―	-0.54%	-259.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IOVA	50 Neutral	$873.33M	-1.83	-53.89%	―	175.62%	19.63%
VIR	50 Neutral	$904.31M	―	-49.06%	―	-78.55%	7.74%
KURA	47 Neutral	$1.04B	―	-65.10%	―	―	-5.18%

Niagen Bioscience Corporate Events

Niagen Bioscience Announces $10 Million Share Buyback

On November 6, 2025, Niagen Bioscience announced that its Board of Directors approved a share repurchase program authorizing the company to buy back up to $10 million of its common stock over the next 24 months. This move reflects the company’s belief in its investment value and represents a strategic use of capital. The repurchases will be conducted in compliance with applicable laws and market conditions, and the program may be modified or terminated at any time. This initiative is expected to impact the company’s market positioning and shareholder value positively.

Niagen Bioscience Reports 33% Q3 Sales Increase

On November 4, 2025, Niagen Bioscience reported a 33% increase in net sales for the third quarter of 2025, reaching $34.0 million, driven by strong Tru Niagen® sales and improved e-commerce performance. The company also launched AboutNAD®, a digital platform for NAD+ research, and expanded its distribution network for Niagen Plus™ IV therapies, reinforcing its leadership in the NAD+ market. The company reaffirmed its full-year outlook for 25% to 30% net sales growth, highlighting its strategic initiatives and operational improvements.

Niagen Bioscience Raises 2025 Sales Outlook Amid FDA Ruling

On October 6, 2025, Niagen Bioscience announced an increase in its full-year 2025 net sales outlook to 25% to 30% year-over-year growth, up from the previous forecast of 22% to 27%. This adjustment reflects the company’s confidence in its market position, particularly following the FDA’s reversal of rulings on the DSHEA drug preclusion rule related to NMN, which could enhance awareness of the NAD+ precursor market. Niagen Bioscience emphasizes the superiority of its Niagen product over NMN supplements, citing issues with NMN products infringing on its patent portfolio and failing to meet label claims. The company’s robust IP protection and focus on quality and efficacy position it strongly in the growing NAD+ supplementation market.